



HRA Pharma Strengthens Board with Experienced Industry Experts

Clower Bergmann, David Colpman and Tim Corn join the new Board to be chaired by Erin Gainer

Paris, March 14, 2017 - Following last year's acquisition by Astorg and its co-investor Goldman Sachs Merchant Banking Division, HRA Pharma announced today a series of key appointments to the company's Board of Directors in line with the company's strategy focused on innovative women's healthcare, consumer healthcare and endocrinology. Clower Bergmann, David Colpman and Timothy Corn join the Company's Board as Independent Directors. Erin Gainer becomes Chair of the new Board.

Clower Bergmann is a highly experienced consumer products executive with more than 30 years of success in leadership roles with leading consumer companies, including Sara Lee, Schering-Plough and Johnson & Johnson. She managed the global women's health business at Johnson & Johnson and remains involved in women's issues through her service to two non-profit boards, EngenderHealth and Women in Need. She is currently an Adjunct Professor in Marketing and General Management at New York University.

David Colpman brings over 30 years of broad experience in business development to HRA Pharma. He is the founder of Colpman Consulting Ltd, a company providing strategic advice to a variety of biotech and pharma companies. Previously he headed business development and licensing at Shire PLC and has also held various BD roles at Purdue, Novo Nordisk A/S, Boots Pharmaceuticals and Glaxo. Mr. Colpman is on the Board of Orexo AB a specialty pharmaceutical company commercialising a product for opioid dependence.

Tim Corn brings in-depth scientific, medical and regulatory knowledge to HRA Pharma. He was previously Chief Medical Officer at Jazz Pharmaceuticals International plc (formerly EUSA Pharma) and Zeneus Pharma. He has held senior clinical and regulatory positions at GlaxoWellcome, MSD Research Laboratories, Athena Neuroscience and Elan as well as in the UK regulatory agency. Dr. Corn has played a key role in more than twenty regulatory approvals in USA and Europe and has solid experience both as a board member and chair of a number of healthcare companies and charities.

Erin Gainer, former CEO of the company from 2009 to 2016, will lead the Board of HRA Pharma, which in addition to the new independent directors includes senior investment professionals from Astorg Partners and Goldman Sachs Merchant Banking Division as well as the company's founder Dr André Ulmann.

“With the appointment of world-class independent directors and the nomination of Erin Gainer as Chair of the Board, the company has enhanced its capabilities to grow further via innovation as well as M&A. Our Board members are tremendous additions to our company, and we will benefit from the diversity of their backgrounds and strong leadership experience,” said Francois Vuillet, CEO of HRA Pharma, “Together with our executive team, HRA Pharma is well prepared to seize business opportunities, tackle challenges and deliver on both its long-term and short-term performance goals.”

Erin Gainer, Chair of HRA Pharma added : “I thank the Board for their confidence in nominating me as Chair and I’m looking forward to working with the Board and the Executive team for HRA Pharma’s continued success.”

HRA Pharma is a leading European specialty pharma focused on women’s health, consumer health and endocrinology with a clear ambition for 2025, to be a trusted partner of consumers and healthcare providers, providing innovative solutions to unmet medical needs. HRA Pharma’s strategy aims at reinforcing the company’s European presence and making inroads into the US market by building on its already strong women’s health, consumer health and endocrinology franchises and pursuing value creation through innovation.

About HRA Pharma

HRA Pharma is a privately-held European pharmaceutical company that designs products and targets therapeutic gaps in the areas of women’s health, consumer health and endocrinology, and uses innovative marketing solutions and socially conscious programs to promote healthy management of drugs and diseases. Headquartered in Paris, France and with subsidiaries across Western Europe, HRA Pharma has built a strong network of R&D, manufacturing, distribution and NGO partners that enables it to satisfy critical patient needs and improve patient health across the globe. Visit www.hra-pharma.com for more information.

###

Media contact

Karina Bugnon

Tel - +33 (0) 1 40 33 11 30

Email – k.bugnon@hra-pharma.com